← Back

Wire · operational-macro

FDA approves stroke prevention drug promising major potential

Published

19 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at medicalbrief.co.za →

◆ Verified

Fusion42 · 19 November 2026 · Fusion42 review

The FDA has approved Bayer's asundexian, branded Sunharbo, as a stroke prevention drug for patients with mild-to-moderate non-cardio-embolic ischaemic stroke or high-risk transient ischaemic attack, marking the first approval of a factor XIa inhibitor with a list price of $748.50 for a 30-day supply and potential peak sales of $3.4bn.

This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.

◆ ◆ The Wire takeaway

The FDA approval opens a lucrative market for stroke prevention therapies, signalling a chance for you to engage with new treatment protocols and partnerships in cardiovascular care.

◆ Coverage

15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026

◆ Related on Wire

◆ Topics

BiotechFDAstroke-preventiondrug-approvalbayerfactor-xia-inhibitor